Epicutantest-TROLAB[R] D2808 Butylglycidether 0,25%

Hauptinformation

  • Handelsname:
  • Epicutantest-TROLAB[R] D2808 Butylglycidether 0,25% Salbe
  • Darreichungsform:
  • Salbe
  • Zusammensetzung:
  • rac-(2R)-2-(Butoxymethyl)oxiran 0.25% (m/V)
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • für die Allgemeinheit:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie das Informationsblatt für die Öffentlichkeit.

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Epicutantest-TROLAB[R] D2808 Butylglycidether 0,25% Salbe
    Deutschland
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
  • Zulassungsnummer:
  • PEI.D.02848.01.1
  • Letzte Änderung:
  • 30-11-2018

12-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

FDA releases guidance with recommendations for drug manufacturers regarding good manufacturing practices and data integrity

FDA - U.S. Food and Drug Administration

30-11-2018

Understanding ASF spread and emergency control concepts in wild boar populations using individual‐based modelling and spatio‐temporal surveillance data

Understanding ASF spread and emergency control concepts in wild boar populations using individual‐based modelling and spatio‐temporal surveillance data

Published on: Thu, 29 Nov 2018 African swine fever (ASF) infection is circulating in Eurasia since a decade within wild boar populations without a demonstrated vector host. Further the infection was recurrently translocated by spatio‐temporal dynamics that is incompatible with wild boar movement characteristics. Management actions are required in areas affected by ASF. Control measures address areas with recent focal introduction and areas with ASF circulating several seasons or endemic occurrence. In v...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx2 related to pesticide residues Objective 2: Linking the processing techniques investigated in regulatory studies with the E

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx2 related to pesticide residues Objective 2: Linking the processing techniques investigated in regulatory studies with the E

Published on: Mon, 26 Nov 2018 In the framework of the project ‘Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx2’ a compendium of representative processing techniques was prepared as a result of Objective 1. In Objective 2 the food / feed items and processes as described in the compendium of Objective 1 were coded using the FoodEx2 coding system. The coding covers the raw agricultural commodities and the food / feed item...

Europe - EFSA - European Food Safety Authority Publications

15-9-2018

Liste der PRAC-Empfehlungen zu Textanpassungen

Liste der PRAC-Empfehlungen zu Textanpassungen

Textanpassungen

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

31-7-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling two lots of Piperacillin and Tazobactam for injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level. One vial from lot# PP0317012-A was found to contain particulate matter, identified as glass within the vial and another vial from lot# PP0317059-A was fo...

FDA - U.S. Food and Drug Administration

29-5-2018

Esmya® (Ulipristalacetat) zur Behandlung von Uterusmyomen: PRAC empfiehlt neue Maßnahmen zur Minimierung des seltenen aber schwerwiegenden Risikos für Leberschädigungen

Esmya® (Ulipristalacetat) zur Behandlung von Uterusmyomen: PRAC empfiehlt neue Maßnahmen zur Minimierung des seltenen aber schwerwiegenden Risikos für Leberschädigungen

Nach Abschluss der Risikobewertung fordert der PRAC regelmäßige Leberfunktionstests während der Behandlung.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

8-5-2018

Piperacillin and Tazobactam for Injection, USP 3.375 g Vials by AuroMedics Pharma: Recall - Vials Contain Particulate Matter

Piperacillin and Tazobactam for Injection, USP 3.375 g Vials by AuroMedics Pharma: Recall - Vials Contain Particulate Matter

Piperacillin and Tazobactam for Injection, USP 3.375 g by AuroMedics Pharma: Recall: Exposure to particulate matter may result in local irritation/swelling or more serious outcomes.

FDA - U.S. Food and Drug Administration

29-9-2017

New practice for follow-up information on adverse reaction reports

New practice for follow-up information on adverse reaction reports

The Danish Medicines Agency has introduced a new practice for the processing of pharmaceutical companies' requests for follow-up information on reports of suspected adverse reactions.

Danish Medicines Agency

1-10-2015

New practice for MIAs

New practice for MIAs

As of 1 October 2015, the Danish Health and Medicines Authority will change the practice for issuing Manufacturing and Importation Authorisations (MIAs) to pharmaceutical companies. This means that all manufacturing activities will be listed on the authorisation.

Danish Medicines Agency

31-3-2015

New guidelines on good distribution practice for APIs

New guidelines on good distribution practice for APIs

The European Commission has published new guidelines on good distribution practice (GDP) for active substances (API) for medicinal products for human use.

Danish Medicines Agency

10-12-2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - December 2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - December 2014

PRAC held its last meeting for this year on 1-4 December 2014. During its December meeting, the PRAC did not initiate or conclude any safety referral. The Committee focused on the broad spectrum of its responsibilities, which cover all aspects of the risk management of the use of medicines.

Danish Medicines Agency

14-11-2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - November 2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - November 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 3-6 November 2014.

Danish Medicines Agency

17-10-2014

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

The EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) recommends strengthening the restrictions on the use of the antiepileptic valproate due to the risk of malformations and developmental problems in children exposed to valproate in the womb.

Danish Medicines Agency

14-10-2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - October 2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - October 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 6-9 October 2014.

Danish Medicines Agency

23-9-2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - September 2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - September 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 8-11 September 2014.

Danish Medicines Agency

29-7-2014

Good laboratory practice in non-clinical trials

Good laboratory practice in non-clinical trials

Clinical Trials Facilitation Group (CTFG) has prepared a document describing the requirements as to good laboratory practice (GLP) in non-clinical trials.

Danish Medicines Agency

15-7-2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - July 2014

Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - July 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 7-10 July 2014.

Danish Medicines Agency

27-2-2014

Paracetamol use during pregnancy

Paracetamol use during pregnancy

A new Danish study suggests a possible connection between mothers' use of paracetamol painkillers during pregnancy and the risk of developing disorders like ADHD (attention deficit hyperactivity disorder) in children.

Danish Medicines Agency

27-1-2014

Questions and answers to new good distribution practice guidelines

Questions and answers to new good distribution practice guidelines

The guidelines on good distribution practice of medicinal products for human use came into force on 7 September 2013. Read our questions and answers to the guidelines.

Danish Medicines Agency

18-12-2018


Q&A: Good clinical practice (GCP)

Q&A: Good clinical practice (GCP)

Q&A: Good clinical practice (GCP)

Europe - EMA - European Medicines Agency

13-12-2018

Paracetamol-ratiopharm® Lösung

Rote - Liste

4-12-2018


Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products – report on actions taken

Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products – report on actions taken

Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products – report on actions taken

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu

Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu

Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-guanidino-1-hexanone hexahydrochloride, decision type: , therapeutic area: , PIP number: P/0134/2018

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Europe - EMA - European Medicines Agency

22-11-2018


Orphan designation: 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide and ivacaftor (tezacaftor and ivacaftor), Treatment of cystic fibrosis, 27/02

Orphan designation: 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide and ivacaftor (tezacaftor and ivacaftor), Treatment of cystic fibrosis, 27/02

Orphan designation: 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide and ivacaftor (tezacaftor and ivacaftor), Treatment of cystic fibrosis, 27/02/2017, Positive

Europe - EMA - European Medicines Agency

12-11-2018

Paracetamol-ratiopharm® Zäpfchen

Rote - Liste

5-9-2018

FDA's Center for Devices and Radiological Health, along with the University of Maryland Center of Excellence in Regulatory Science and Innovation will be hosting a workshop on #PatientEngagement in Real-World Evidence Lessons and Best Practices for medica

FDA's Center for Devices and Radiological Health, along with the University of Maryland Center of Excellence in Regulatory Science and Innovation will be hosting a workshop on #PatientEngagement in Real-World Evidence Lessons and Best Practices for medica

FDA's Center for Devices and Radiological Health, along with the University of Maryland Center of Excellence in Regulatory Science and Innovation will be hosting a workshop on #PatientEngagement in Real-World Evidence Lessons and Best Practices for medical devices on Sept. 9th

FDA - U.S. Food and Drug Administration

30-8-2018

Modified release paracetamol

Modified release paracetamol

Advisory Committee on Medicines Scheduling to consider upscheduling of modified release paracetamol to 'Pharmacist Only'

Therapeutic Goods Administration - Australia

29-8-2018

Prac-Tic (Elanco GmbH)

Prac-Tic (Elanco GmbH)

Prac-Tic (Active substance: pyriprole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5784 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/000103/T/0025

Europe -DG Health and Food Safety

21-8-2018

Do you wear contact lenses? This rare but serious infection of the eye primarily affects people who wear contact lenses. #GuessthePathogen, and make sure to practice healthy habits  http://bit.ly/2ifnt2O  #ContactLensHealthWeekpic.twitter.com/ZBZAAtbrVr

Do you wear contact lenses? This rare but serious infection of the eye primarily affects people who wear contact lenses. #GuessthePathogen, and make sure to practice healthy habits http://bit.ly/2ifnt2O  #ContactLensHealthWeekpic.twitter.com/ZBZAAtbrVr

Do you wear contact lenses? This rare but serious infection of the eye primarily affects people who wear contact lenses. #GuessthePathogen, and make sure to practice healthy habits http://bit.ly/2ifnt2O  #ContactLensHealthWeek pic.twitter.com/ZBZAAtbrVr

FDA - U.S. Food and Drug Administration

28-6-2018

Here are three main practices for protecting yourself online: be sure your internet connection is secure, be careful what you download, and always be careful what you post! #InternetSafetyMonthpic.twitter.com/ZpJ0aas1N4

Here are three main practices for protecting yourself online: be sure your internet connection is secure, be careful what you download, and always be careful what you post! #InternetSafetyMonthpic.twitter.com/ZpJ0aas1N4

Here are three main practices for protecting yourself online: be sure your internet connection is secure, be careful what you download, and always be careful what you post! #InternetSafetyMonth pic.twitter.com/ZpJ0aas1N4

FDA - U.S. Food and Drug Administration

23-5-2018

Scientific guideline:  Draft guideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with good clinical practice and good manufacturing practice, draft: consul

Scientific guideline: Draft guideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with good clinical practice and good manufacturing practice, draft: consul

The guideline lays down the principles for the two-step release and shipping of the investigational medicinal products by the qualified person and the sponsor. The guideline also describes the areas of interface between the manufacturer and the sponsor and the required contractual agreements.

Europe - EMA - European Medicines Agency